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| INTRODUCTION
Venous thromboembolism (VTE) is major source of morbidity and mortality in cancer patients. 1, 2 Incidence rates of cancer-associated thrombosis (CAT) vary with cancer type, stage, treatment, and comorbidities, but it is estimated that approximately 15% to 20% of cancer patients will develop a venous thromboembolic episode at some point during the course of their illness. 3, 4 Treatment of CAT is particularly challenging, with higher rates of recurrence and major bleeding than for non-cancer patients with VTE. 5 Low-molecular-weight heparins (LMWHs) have been shown to be superior to vitamin K antagonists such as warfarin, 6 although LMWHs are expensive and the injections are burdensome to patients, leading to poor compliance. 7 Across several studies of an LMWH to treat CAT, the rates of VTE recurrence and major bleeding with LWMH are approximately 7% to 8% and 4% to 5%, respectively. [6] [7] [8] There is a growing body of data supporting the effective use of direct oral anticoagulants (DOACs) for treatment of CAT.
Rivaroxaban was the first DOAC approved by the US Food and Drug Administration (FDA) for treatment of VTE, in 2012. The approval did not address the specific niche of cancer, either supporting use or cautioning against use, as the 2 pivotal phase III trials leading to approval included approximately 5.6% of cancer patients in the rivaroxaban-treated arms. 9, 10 A subsequent subgroup analysis of the EINSTEIN trials of cancer patients did not indicate any signal of particular risk in the cancer patients.
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In 2013, we designed a Clinical Pathway to guide use of rivaroxaban in cancer patients within Memorial Sloan Kettering Cancer
Center. The key criteria were to recommend against use of rivaroxaban in patients with active luminal gastrointestinal (GI) tract or genitourinary (GU) tract lesions. In addition, we employed a modest dose reduction in the elderly. In 2017, we published outcomes of our first 200-patient cohort of patients with CAT treated with rivaroxaban, following our Clinical Pathway, and demonstrated both low rates of recurrent VTE (4.4%; 95% confidence interval [CI], 1.4%-7.4%) and major bleeding (2.2%; 95% CI, 0%-4.2%) at 6 months.
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Since our first report of our single institutional experience, 2 randomized clinical trials (RCTs) comparing a DOAC with an LMWH have been published, the HOKUSAI VTE Cancer trial of edoxaban 13 and the SELECT-D trial of rivaroxaban.
14 Both studies demonstrated a trend toward lower rates of recurrent V TE with the DOAC but with higher rates of bleeding, particularly in the GI and GU tracts. 13, 14 We now report on efficacy and safety outcomes in an expanded cohort of 1072 patients with CAT, who received rivaroxaban for treatment. To our knowledge, this is the largest reported population of cancer patients treated with a DOAC.
| MATERIALS AND METHODS

| Clinical pathway
The Clinical Pathway was designed to help guide clinician use of rivaroxaban for CAT within our institution (Appendix S1). Key points of the Clinical Pathway include patient selection. Active luminal lesions of the GI or GU tract were considered contraindications.
Bioavailability of rivaroxaban is approximately > 80%, 15 but active drug remains in the upper GI lumen. Similarly, rivaroxaban and other DOACs are excreted in the urine at biologically active concentrations. 16 In the presence of known luminal lesions of the GI or GU tract, an LMWH was recommended instead. Untreated central nervous system neoplasms were also a considered a contraindication to the use of rivaroxaban, as at the time there were no published data on safety in that setting.
In general, we followed the FDA-approved dosing guidelines, including contraindication in the presence of renal insufficiency (with creatinine clearance values < 30 mL/min) and possible drug interactions involving the inhibitors or inducers of cytochrome P450
3A4 and P-glycoprotein efflux pump. However, for patients aged 75 years or older, we recommended a reduced dose of 10 mg orally twice a day for 3 weeks, followed by 15 mg daily. This was based on the known 4-fold increased risk of life-threatening and fatal hemorrhagic complications in patients aged 80 years or older, with the superimposed increased risk of life-threatening hemorrhage in cancer patients. 
Essentials
• Rivaroxaban is effective treatment of cancer-associated thrombosis (CAT) but with increased bleeding.
• We describe results of an institutional protocol for CAT treatment with rivaroxaban.
• We recommended avoiding rivaroxaban in patients with gastrointestinal or genitourinary tract lesions, and dose reduction for age ≥ 75.
• Results showed acceptable efficacy and safety. 
| Statistical analysis
The 6-month incidence of a recurrent VTE, major bleed, and CRNMB were separately estimated using cumulative incidence functions. Each of the 3 event types was considered a competing risk for the remaining event types; in addition, death in the absence of each event was considered a competing risk. In the primary analysis, patients entered the risk set upon starting rivaroxaban following the index VTE. A sensitivity analysis was conducted among patients who started rivaroxaban immediately following the VTE. Patients without an event were censored upon discontinuation of rivaroxaban or upon completion of the 6-month analysis window, whichever came first. The 6-month cumulative incidence of mortality was similarly estimated; however, for this end point, there were no competing events, and patients were not censored upon discontinuation of rivaroxaban if occurring before the 6-month time point.
These end points were also estimated among patients above and below age 75. All analyses were done in the R v3. Patients who received rivaroxaban: n = 1815
Patients with a lower extremity DVT and/or PE: n = 1269
Patients who received rivaroxaban during their first 6 months on anticoagulation: n = 1086 n = 1072
Patients with observation time after 1-01-2014:
17% were aged ≥75 years at the time of the index VTE episode.
The most common cancers were lung, gynecologic, pancreas, 
| Clinical end points
Frequencies of clinical end points occurring while the patients were on rivaroxaban are presented in Table 2 . No patients were lost to follow-up. The cumulative incidence analysis is presented in Table 3 and plots for competing end points are shown in Figure 1 .
In the unadjusted analysis ( The routine practice at Memorial Sloan Kettering Cancer Center is to discontinue anticoagulation when patients are transferred to hospice, or otherwise cease cancer-directed therapy. See Figure 1 for overall mortality rate of the cohort. CRNMB, clinically relevant nonmajor bleeding; DVT, deep vein thrombosis; PE, pulmonary embolism; VTE, venous thrombolism.
In a cumulative incidence analysis (Table 3 and Figure 2 ), the 6-month incidence of a recurrent VTE was 4.2% (95% CI, 2.7-5.7), major bleeding was 2.2% (95% CI, 1.1-3.2), and CRNMB was 5.5% (95% CI, 3.7-7.1). The remaining patients were censored at 6 months or censored due to discontinuation of rivaroxaban for a reason other than reaching 1 of the prespecified clinical end points.
To determine the mortality cumulative incidence, we needed to take into account that a large number of patients would be censored shortly before reaching this end point, as anticoagulation is typically discontinued upon admission to a hospice program. Therefore, we determined the incidence of death at any time during the 6-month period after the index VTE event, whether the patient was on rivaroxaban or another anticoagulant or had already reached an end point of recurrent thrombosis or bleeding. The 6-month incidence of death in the whole cohort was 22.2% (95% CI, 19.3%-24.8%).
All bleeding episodes were reviewed (Table 4) . GI bleeding accounted for 32% of CRNMB and 73% of major bleeds. Cancers of the GI lumen did not appear to be overrepresented for major bleeding in general, nor the GI tract specifically (Table 5 ). Only 1 of the 100 patients with colorectal cancer and 1 of the 40 with gastric/esophageal cancer experienced a major bleed. There were no fatal hemorrhages and no intracranial hemorrhages. And although not primary end points, there were no recognized episodes of known myocardial infarction or ischemic stroke.
As this was a QA initiative, we reviewed all cases of major bleeding (Table 6 ). An anatomic lesion was identified, either prior to the hemorrhage or in the course of evaluation in 6 of the 11 total major GI bleeding episodes overall, and in 2 of the 4 other major bleeding events. Thus, in the entire cohort, there were only 7 major bleeds that occurred in the absence of an identified anatomic lesion.
| Analysis of elderly
One hundred eighty-two patients (17%) of the cohort were aged ≥75 years at the time of the index VTE episode. The cumulative incidences of recurrent VTE, major bleeding, CRNMB, and all-cause 6-month mortality did not differ significantly for patients under 75 years of age vs. older individuals (Table 3) .
| DISCUSSION
To our knowledge, this is the largest prospective cohort study assessing the use of rivaroxaban for CAT. Our goal was to assess and validate our Clinical Pathway for the use of rivaroxaban in treatment of CAT. The estimated 6-month risks of recurrent VTE and major bleeding are similar to the results of our earlier, smaller series. 12 We maintained low rates of both recurrent VTE and major bleeding.
One essential aspect of our Clinical Pathway was to guide the appropriate choice of anticoagulant for CAT, by anticipating situations where rivaroxaban would be expected to be associated with a See Statistical Analysis3.2 in Methods for full description. Recurrent VTE, major bleed, and CRNMB leading to discontinuation of rivaroxaban for ≥7 days were separately estimated using cumulative incidence functions. For the 6-mo cumulative incidence of mortality end point, there were no competing events, and patients were not censored upon discontinuation of rivaroxaban if occurring before the 6-mo time point. CI, confidence interval; CRNMB, clinically relevant nonmajor bleeding; VTE, venous thrombolism.
TA B L E 3 Day 180 analysis adjusting for competing risks F I G U R E 2 Cumulative incidence of primary end points.
Competing risk analysis while patients were on rivaroxaban. End points were recurrent thrombosis, major bleeding, and CRNMB leading to discontinuation of rivaroxaban for at least 7 days. Death was also a competing end point. However, most deaths occurred when patients were transferred to hospice or only receiving supportive care, and rivaroxaban was discontinued. To more meaningfully represent the overall mortality rate of the cohort, all deaths are included, including after rivaroxaban was discontinued. VTE, venous thromboembolism LMWH in those patients. However, more recent reports support the use of a DOAC in patients with primary or metastatic cancer of the brain.
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Our initial experience with our Clinical Pathway was reported in early 2017. 12 Since then, 2 prospective RCTs of a DOAC vs.
LWMH for CAT have been reported. Any comparison of outcomes from our single-arm QA study with results from randomized, prospective clinical trials is limited, as the analysis we conducted was on-treatment for most end points, in contrast to intention to treat for prospective trials. With that limitation acknowledged, the 6-month rate of recurrent VTE observed in our cohort was similar to results reported in the recent clinical trials of rivaroxaban and edoxaban. 13, 14 A major difference in the results of the RCTs and our singlearm cohort results is in the bleeding outcomes. The HOKUSAI VTE Cancer trial reported a significantly higher rate of major bleeding with edoxaban, compared with LMWH, particularly in patients with GI or GU cancer. 13 The authors did not specify if the primary GI or GU lesions were still present at the time of anticoagulation start.
During an interim analysis in the SELECT-D trial, "The DSMC (Data and Safety Monitoring Committee) also noted a nonsignificant difference in major bleeding between arms in the 19 patients with cancer of the esophagus or gastroesophageal junction. These cancers were TA B L E 6 Anatomic contribution to major bleeding subsequently excluded from enrollment as a precautionary measure." 14 The higher rates of GI or GU bleeding in the 2 recent RCTs, which had not excluded patients based on GI or GU tract pathology, supports our Clinical Pathway recommendations in this area.
Our detailed analysis of all major bleeding episodes was notable in how few truly "spontaneous" major hemorrhages there were. Of the 15 major bleeding episodes, 8 had an identified anatomic lesion that made the patient particularly at risk for bleeding, such as cancer directly involving the gastrointestinal lumen. Only 7 patients experienced a major bleed without an identified anatomic lesion contributing. The fact that most of the anatomic risks were identified and known before the hemorrhage also suggests we can further optimize safety.
For our analysis, we prespecified CRNMB leading to discontinuation of rivaroxaban for at least 7 days, a different definition from the 2 recent RCTs. 13, 14 Therefore, no comparison of rates of CRNMB can be made between our results and the SELECT-D and HOKUSAI VTE Cancer trial.
The 1 key area where our Clinical Pathway diverges from the FDA-approved package insert/dosing guidelines is our approach to dose reduction in the elderly. We felt this was appropriate due to the known 4-fold increased risk of fatal or life-threatening hemorrhage in the elderly with the additional risk of bleeding associated with cancer. 5, 17, 18 The elderly had similar rates of recurrent thrombosis, major bleeding, and CRNMB as the patients under 75 years old, supporting our practice of dose modification in the elderly.
Based on our Clinical Pathway and our institutional experience, for cancer patients without GI or GU lesions and contraindications, rivaroxaban may be an effective and safe choice. Plus, rivaroxaban spares the cost and burden to the patient of LMWH injections.
However, for patients with GI or GU lesions, an LMWH may be the most appropriate choice. Drug interactions with rivaroxaban may also be a consideration in some patients.
There are additional questions to address. We do not have validation of a rivaroxaban dose modification strategy in the setting of thrombocytopenia, as has been provided for enoxaparin. CAT the drug that will maximize safety and efficacy.
| LIMITATIONS
There are several limitations to our cohort study. Selection bias could come from potential risk factors for bleeding not listed in the Clinical Pathway which, in the mind of the treating physician, would prompt them to use LMWH instead. A perceived (real or imagined) higher risk of recurrent VTE could also tilt the balance in favor of starting the time-proven LMWH standard in some individuals. However, the choice of initial anticoagulant was usually made by an emergency department physician or a treating oncologist. They were educated about the Clinical Pathway, but ultimately it was their choice of anticoagulant.
Detection bias could have occurred due to software or observer error when assessing clinical notes for end points. However, the keyword list used for the initial computer-driven review of the EMR is extensive. Further, after electronic capture, all relevant notes were then reviewed by at least 2 members of the investigator team. In addition, all radiographic or other imaging studies were reviewed for thrombosis, and the pharmacy records were reviewed for anticoagulant orders.
Finally, as this was an institutional cohort study, adjudication was performed by the treating physicians, not an independent team.
| CONCLUSIONS
Our new QA initiative report has further validated the effective and safe use of rivaroxaban for treatment of cancer-associated thrombosis. The risk of recurrent thrombosis is as low or lower than historical controls with LMWH. Based on the pharmacokinetics of rivaroxaban, we have developed and validated a Clinical
Pathway to identify when rivaroxaban should or should not be used.
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